Clinical Trials Logo

Metabolic Syndrome clinical trials

View clinical trials related to Metabolic Syndrome.

Filter by:

NCT ID: NCT03976336 Recruiting - Metabolic Syndrome Clinical Trials

Evaluating the Tolerability and Effects of Berberine on Major Metabolic Biomarkers: A Pilot Study

Start date: August 20, 2019
Phase: N/A
Study type: Interventional

Berberine is a dietary supplement that comes from the roots, stems, and bark of various plants and has been used for centuries in traditional Chinese medicine. It may help lower cholesterol, lower blood sugar, and reduce inflammation.Very few studies have been done in the United States to show how berberine effects cholesterol and blood sugar. This study is looking to see how berberine changes cholesterol and blood sugar, and to see how well it is tolerated.Berberine is not a prescription medication but it appears to have similar actions to common prescription medications to lower cholesterol like statins, and to lower blood sugar like metformin. We are studying berberine to see if it may be a good option for people that do not want to take prescription medications.

NCT ID: NCT03973996 Completed - Metabolic Syndrome Clinical Trials

Gut-level Antiinflammatory Activities of Green Tea in Metabolic Syndrome

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

This study evaluates dietary green tea extract to improve gut health and inflammation in persons with metabolic syndrome and healthy adults. Participants will complete two phases of intervention in random order in which they will consume green tea extract or placebo for one month and then switch to the opposite treatment for an additional month.

NCT ID: NCT03969264 Completed - Clinical trials for Risk for Metabolic Syndrome

Tree Nut Consumption to Reduce Abdominal Adiposity

Start date: July 15, 2019
Phase: N/A
Study type: Interventional

A major contributing factor to the rising waist circumference of U.S. young adults is the increase in snacking behavior. Both the frequency of snacking during the day and the percentage of adults who engage in snacking has risen; national data indicates snacking comprises 15-25% of the total daily caloric intake of young and middle-aged adults. The overarching hypothesis, based on significant preliminary data, is that the quantity and metabolic function of abdominal fat is a key intermediary factor by which greater tree nut consumption reduces ectopic lipid storage (including the accumulation of intra-abdominal [visceral] fat), improves fatty acid and lipoprotein metabolism, reduces systemic inflammation and insulin resistance, and thus, reduces risk for MetS in millennial-generation age individuals.

NCT ID: NCT03966846 Completed - Obesity Clinical Trials

Kefir and Metabolic Syndrome

Start date: March 2015
Phase: N/A
Study type: Interventional

Metabolic syndrome is a cluster of metabolic disorders which increases the risk for diabetes and cardiovascular disease. In recent years, research has shown that probiotics may have positive effects on metabolic syndrome components. Although several health-promoting effects of kefir, have been suggested, there is limited evidence for its potential effect on metabolic syndrome. Therefore, it is necessary to clarify the effects of kefir on metabolic disorders including obesity, dyslipidemia, diabetes, and hypertension. To address the research gap, this study aimed to investigate the effects of daily kefir consumption on metabolic syndrome components, inflammatory response and gut microbiota composition in adults with MetS. The study was planned as a randomized, controlled, parallel design and completed with a total of 62 individuals who were diagnosed with metabolic syndrome according to the International Diabetes Federation (IDF) criteria. Participants were randomized into two groups and received daily 180 ml of kefir (n=31) or milk (as control) (n=31) for 12 weeks. Participants were assessed at baseline, week 4, week 8, and week 12 and at all controls dietary records, anthropometric measurements, and blood samples were collected. At baseline and 12th-week fecal samples were also collected in order to analyze gut microbiota composition.

NCT ID: NCT03960216 Completed - Metabolic Syndrome Clinical Trials

Effects of Periodontal Therapy in Patients With Metabolic Syndrome

MetS
Start date: November 28, 2012
Phase: N/A
Study type: Interventional

A 6-month, parallel-arm, investigator-masked, randomized clinical trial was conducted in patients with MetS and severe periodontitis. Participants were randomly assigned to an Intensive Periodontal Treatment group (IPT; scaling and root planing and azithromycin capsules 500mg/24h/3days) or to a Minimal Periodontal Treatment group (MPT; professional plaque removal and placebo capsules). Blood and subgingival microbiological samples were collected at baseline, 3 and 6 months after therapy. The primary outcome was between-group difference in C-reactive protein (CRP). Secondary outcomes included HbA1c, lipids, α-1 antitrypsin, fibrinogen levels and subgingival microbiota assessment.

NCT ID: NCT03956433 Completed - Metabolic Syndrome Clinical Trials

Effect of Bioactive Enriched Food on Markers of Metabolic Syndrome

PATHWAY-27
Start date: September 1, 2014
Phase: N/A
Study type: Interventional

This pilot study will investigate the enrichment type, in pancakes, most effective at improving markers of metabolic syndrome. Ready-made pancakes enriched with either docosahexaenoic acid (DHA), beta-glucan (BG) or anthocyanins (AC), alone or in combination of DHA+BG or DHA+AC, will be consumed for 4 weeks.

NCT ID: NCT03948061 Completed - Obesity Clinical Trials

Cardiometabolic Effects of Sweet Cherry Juice

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

This study aims to determine the effects of consuming sweet cherry juice on cardiovascular function, glucose regulation, and lipid status in overweight human subjects. The investigators hypothesize that sweet cherry juice consumption will improve metabolic and physiological status in overweight persons compared to a placebo.

NCT ID: NCT03938571 Active, not recruiting - Obesity Clinical Trials

Standard Duodenal Switch vs. Single Anastomosis Duodeno-Ileostomy Duodenal Switch

Start date: August 2016
Phase: N/A
Study type: Interventional

The aim of the Torsby I Trial is to identify differences and similarities between a standard duodenal switch (DS) and a single-anastomosis duodeno-ileostomy (SADI) regarding effect on weight, comorbidities and malnutrition.

NCT ID: NCT03937960 Completed - Obesity Clinical Trials

Effect of Low Carbohydrate Versus Low Fat Diet in the Treatment of Dyslipidemia in Obese Children With Metabolic Syndrome

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Two-arm, parallel design with children between the ages of 10 - 18 with obesity and metabolic syndrome randomized (15 per group) to reduced-carbohydrate diet or a reduced-fat diet for 8 weeks.

NCT ID: NCT03935854 Completed - Obesity Clinical Trials

Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar or Schizophrenia Illness

Start date: February 13, 2019
Phase: N/A
Study type: Interventional

To initiate a low-carbohydrate, high-fat (LCHF) or ketogenic dietary (KD) intervention among a cohort of outpatients with either schizophrenia or bipolar illness who also have metabolic abnormalities, overweight/obesity, and/or are currently taking psychotropic medications experiencing metabolic side effects.